非布司他逐渐增量在治疗痛风合并慢性肾脏病中的应用

    Application of gradual incremental protocol of febuxostat for gout complicated with chronic kidney disease

    • 摘要: 目的 探讨非布司他单药逐渐增量与合用秋水仙碱在治疗痛风合并慢性肾脏病(Chronic kidney disease,CKD)降低血尿酸、预防痛风发作中的应用。方法 回顾性分析南京医科大学附属南京医院收治的90例痛风急性发作合并CKD3~4期患者临床资料,90例患者分为3组,每组30例。A组逐渐增量应用非布司他(从20 mg/d到40 mg/d),B组定量应用非布司他(40 mg/d)和秋水仙碱(0.5 mg/次,2 d 1次),C组定量应用非布司他(40 mg/d)。观察3组患者治疗前后的痛风发作频率、血尿酸(uric acid,UA)水平、估算肾小球滤过率(estimated glomerular filtration rate,eGFR)、蛋白尿指标的变化,记录不良反应发生率。结果 3组患者3个月内的痛风急性发作次数比较,C组的发作次数最多,A、B两组的发作次数较为接近。与治疗前相比,三组治疗后的第一、二、三个月的血清UA水平较前均明显降低(P<0.05)。第一、二个月后A组的血清UA水平高于B、C两组,且差异有统计学意义(P<0.05)。与治疗前相比,3组治疗后的血肌酐水平均呈下降趋势。治疗后第一个月与治疗前相比差异无统计学意义。治疗后第二个月A组的血肌酐水平较治疗前明显降低(P<0.05)。治疗后第三个月A、C组的血肌酐水平较治疗前明显降低(P<0.05)。与治疗前相比,3组治疗后的eGFR水平均呈上升趋势。治疗后第一个月与治疗前相比差异无统计学意义。治疗后第二、三个月A、C组的eGFR水平较治疗前明显降低(P<0.05)。与治疗前相比,A、C两组治疗后的蛋白尿水平均呈下降趋势,B组较前升高。相比治疗前,A组患者治疗后第二、三个月尿蛋白水平较前明显降低(P<0.05)。3组患者治疗期间均未发生严重不良反应,B组有4例发生轻度腹泻,B组的不良反应发生率略高于另外两组,但组间差异无统计学意义(P>0.05)。结论 非布司他逐渐增量方案治疗痛风合并慢性肾脏病可有效减少痛风急性发作,临床疗效显著,并且逐步增量方案的肾保护作用显著,且不良反应少,是治疗痛风合并慢性肾脏病的理想用药方案。

       

      Abstract: Objective To explore the application of gradual incremental protocol of febuxostat plus colchicine in reducing serum uric acid and preventing attack in gout complicated with chronic kidney disease (CKD).Methods Ninety cases of acute gout with CKD3-4 were divided into three groups (n=30 each).Group A received febuxostat (20-40 mg/d),group B febuxostat (40 mg/d)plus colchicine (0.5 mg/every other day) and group C febuxostat (40 mg/d).Frequency of gout attack,serum uric acid (UA),glomerular filtration rate (eGFR) and proteinuria were observed before and after treatment and the incidence of adverse reactions was recorded.Results Among three groups,group C group had the most frequent attacks while groups A and B were relatively close.As compared with pre-treatment,serum UA levels of three groups at Month 1/2/3 were significantly lower than those pre-treatment (P<0.05).At Month 3,serum UA level was higher in group A than that in group B/C and the difference was significant (P<0.05).As compared with pre-treatment,serum creatinine levels of three groups showed a downward trend post-treatment.Serum creatinine level at Month 3 post-treatment was significantly lower than that pre-treatment (P<0.05).As compared with pre-treatment,serum creatinine level was lower in group B than that in group A/C at Month 3.As compared with pre-treatment,eGFR levels of three groups showed an upward trend.Serum eGFR of three groups at Month 3 post-treatment was significantly higher than that pre-treatment (P<0.05).The level of eGFR was similar in group B at Month 3 post-treatment (P>0.05).However,increase was higher in group A than that in group B.As compared with pre-treatment,proteinuria of group A/C declined after treatment,but worsened in group B.As compared with pre-treatment,urinary protein level of group A/C decreased markedly at Month 3 post-treatment (P<0.05) and increased in group B.No serious adverse reactions occurred among three groups during treatment.Four cases of mild diarrhea occurred in group B.The incidence of adverse reactions was slightly higher in group B than that in group A/C.However,no significant difference existed between two groups (P>0.05).Conclusion For gout complicated with CKD,gradual incremental protocol of febuxostat can effectively reduce acute attack with a significant clinical efficacy.It offers marked renal protection and fewer adverse reactions.

       

    /

    返回文章
    返回